Ae­glea's en­gi­neered en­zyme flops out­comes test in rare meta­bol­ic dis­ease. Is re­duc­ing a key bio­mark­er enough for an ap­proval?

Austin’s Ae­glea Bio­Ther­a­peu­tics is hop­ing to blaze a path re­duc­ing a key amino acid bio­mark­er for a rare wast­ing meta­bol­ic dis­ease with its en­gi­neered en­zyme …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER